NeuroSense Therapeutics Outlines Phase 3 Timeline For PrimeC In ALS, Updates Canadian Regulatory Pathway, Highlights Partnership Talks With A Global Pharmaceutical Company; Says "We Have No Immediate Plans For Additional Capital Raising, We Maintain...

BenzingaApr 24 09:12 ET

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

PR NewswireApr 24 09:09 ET

NeuroSense Therapeutics Reports Phase 2b MicroRNA Data, Highlighting PrimeC's Promise As A Disease-Modifying ALS Treatment

BenzingaApr 9 08:32 ET

Express News | Neurosense Therapeutics Announces Transformative Phase 2B Microrna Data, Highlighting Primec's Promise as a Disease-Modifying ALS Treatment

ReutersApr 9 08:30 ET

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

PR NewswireApr 9 08:30 ET

Express News | NeuroSense Therapeutics FY 2024 GAAP EPS $(0.54) Beats $(0.60) Estimate

BenzingaApr 7 17:27 ET